{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=FOLFIRINOX+Regimen&page=2", "query": { "intervention": "FOLFIRINOX Regimen", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=FOLFIRINOX+Regimen&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-09-26T11:23:42.738Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04683315", "title": "PurIST Classification-Guided Adaptive Neoadjuvant Chemotherapy by RNA Expression Profiling of EUS Aspiration Samples", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Pancreatic Cancer" ], "interventions": [ { "name": "mFOLFIRINOX Treatment Regimen", "type": "DRUG" }, { "name": "Gemcitabine/Nab-paclitaxel Treatment Regimen", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Medical College of Wisconsin", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 84, "start_date": "2021-04-01", "completion_date": "2028-12-31", "has_results": false, "last_update_posted_date": "2026-03-05", "last_synced_at": "2026-09-26T11:23:42.738Z", "location_count": 2, "location_summary": "Scottsdale, Arizona • Milwaukee, Wisconsin", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Milwaukee", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT04683315" }, { "nct_id": "NCT03899636", "title": "A Pivotal Study of Safety and Effectiveness of NanoKnife IRE for Stage 3 Pancreatic Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Stage III Pancreatic Cancer" ], "interventions": [ { "name": "Modified FOLFIRINOX Regimen", "type": "DRUG" }, { "name": "NanoKnife System", "type": "DEVICE" } ], "intervention_types": [ "DRUG", "DEVICE" ], "sponsor": "Angiodynamics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 528, "start_date": "2021-02-23", "completion_date": "2025-04", "has_results": false, "last_update_posted_date": "2025-02-12", "last_synced_at": "2026-09-26T11:23:42.738Z", "location_count": 6, "location_summary": "Miami, Florida • Tampa, Florida • Arlington Heights, Illinois + 3 more", "locations": [ { "city": "Miami", "state": "Florida" }, { "city": "Tampa", "state": "Florida" }, { "city": "Arlington Heights", "state": "Illinois" }, { "city": "Louisville", "state": "Kentucky" }, { "city": "Easton", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT03899636" }, { "nct_id": "NCT01839799", "title": "A Randomized Phase II/Genomic Trial of Two Chemotherapy Regimens in Patients With Resected Pancreatic Adenocarcinoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Pancreatic Adenocarcinoma" ], "interventions": [ { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Abraxane", "type": "DRUG" }, { "name": "FOLFIRINOX", "type": "DRUG" }, { "name": "Chemoradiation", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "Abramson Cancer Center at Penn Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 32, "start_date": "2013-04", "completion_date": "2017-07", "has_results": true, "last_update_posted_date": "2021-02-25", "last_synced_at": "2026-09-26T11:23:42.738Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT01839799" }, { "nct_id": "NCT03977233", "title": "Tumor Subtypes in Subjects on FOLFIRINOX With Non-Metastatic Pancreatic Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Pancreatic Ductal Adenocarcinoma (PDAC)", "Cancer of Pancreas", "Pancreatic Cancer, Adult", "Pancreas Adenocarcinoma", "Pancreatic Neoplasms", "Pancreatic Cancer Non-resectable", "Pancreatic Cancer Resectable" ], "interventions": [ { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "Leucovorin", "type": "DRUG" }, { "name": "Irinotecan Hydrochloride", "type": "DRUG" }, { "name": "5-FU", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "UNC Lineberger Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 45, "start_date": "2019-06-12", "completion_date": "2030-01", "has_results": false, "last_update_posted_date": "2026-01-13", "last_synced_at": "2026-09-26T11:23:42.738Z", "location_count": 1, "location_summary": "Chapel Hill, North Carolina", "locations": [ { "city": "Chapel Hill", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT03977233" }, { "nct_id": "NCT01726582", "title": "Pancreas Cancer: Molecular Profiling as a Guide to Therapy Before and After Surgery (\"Personalized Medicine\")", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Pancreatic Adenocarcinoma" ], "interventions": [ { "name": "Milestone 1: Targeted chemotherapy prior to surgery", "type": "DRUG" }, { "name": "Milestone 2: Chemoradiotherapy (cXRT)", "type": "RADIATION" }, { "name": "Milestone 3: Targeted chemotherapy prior to surgery", "type": "DRUG" }, { "name": "Milestone 3: Chemoradiotherapy (cXRT)", "type": "RADIATION" }, { "name": "Milestone 4: standard FOLFIRINOX chemotherapy prior to surgery", "type": "DRUG" }, { "name": "Milestone 4: Chemoradiotherapy (cXRT)", "type": "RADIATION" }, { "name": "Milestone 5: Targeted chemotherapy after surgery", "type": "DRUG" }, { "name": "Milestone 5: Chemoradiotherapy (cXRT)", "type": "RADIATION" }, { "name": "Milestone 6: Gemcitabine after surgery", "type": "DRUG" }, { "name": "Milestone 6: Chemoradiotherapy (cXRT)", "type": "RADIATION" }, { "name": "Milestone 7: Chemoradiotherapy (cXRT)", "type": "RADIATION" }, { "name": "Milestone 8: Targeted chemotherapy after surgery", "type": "DRUG" }, { "name": "Milestone 9: Gemcitabine after surgery", "type": "DRUG" }, { "name": "Milestone 10: No additional therapy after surgery", "type": "OTHER" } ], "intervention_types": [ "DRUG", "RADIATION", "OTHER" ], "sponsor": "Medical College of Wisconsin", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 229, "start_date": "2011-11", "completion_date": "2022-04-11", "has_results": true, "last_update_posted_date": "2023-08-14", "last_synced_at": "2026-09-26T11:23:42.738Z", "location_count": 2, "location_summary": "Cincinnati, Ohio • Milwaukee, Wisconsin", "locations": [ { "city": "Cincinnati", "state": "Ohio" }, { "city": "Milwaukee", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT01726582" }, { "nct_id": "NCT05458219", "title": "A First-in-human Study of IBI343 in Subjects With Locally Advanced Unresectable or Metastatic Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Locally Advanced Unresectable or Metastatic Solid Tumors" ], "interventions": [ { "name": "IBI343", "type": "DRUG" }, { "name": "FOLFIRINOX/mFOLFIRINOX", "type": "DRUG" }, { "name": "mFOLFOX", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Innovent Biologics (Suzhou) Co. Ltd.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 470, "start_date": "2022-10-26", "completion_date": "2027-12-31", "has_results": false, "last_update_posted_date": "2026-05-04", "last_synced_at": "2026-09-26T11:23:42.738Z", "location_count": 3, "location_summary": "Austin, Texas • Irving, Texas • San Antonio, Texas", "locations": [ { "city": "Austin", "state": "Texas" }, { "city": "Irving", "state": "Texas" }, { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05458219" }, { "nct_id": "NCT04672005", "title": "Modified FOLFIRINOX Alternated With Biweekly Gemcitabine Plus Nab-Paclitaxel Untreated Pancreatic Cancer", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Pancreatic Cancer" ], "interventions": [ { "name": "Folfirinox alternating with Gemcitabine-nab-Paclitaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Lyudmyla Berim", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "2021-01-06", "completion_date": "2025-06-01", "has_results": false, "last_update_posted_date": "2024-05-16", "last_synced_at": "2026-09-26T11:23:42.738Z", "location_count": 7, "location_summary": "Hamilton, New Jersey • Jersey City, New Jersey • Livingston, New Jersey + 4 more", "locations": [ { "city": "Hamilton", "state": "New Jersey" }, { "city": "Jersey City", "state": "New Jersey" }, { "city": "Livingston", "state": "New Jersey" }, { "city": "Long Branch", "state": "New Jersey" }, { "city": "New Brunswick", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT04672005" }, { "nct_id": "NCT04594772", "title": "Adaptive Approach to Neoadjuvant Therapy to Maximize Resection Rates for Pancreatic Adenocarcinoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Pancreas Cancer" ], "interventions": [ { "name": "Folfirinox", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "radiation therapy", "type": "RADIATION" }, { "name": "Pancreatectomy", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "RADIATION", "PROCEDURE" ], "sponsor": "University of Cincinnati", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 32, "start_date": "2021-03-17", "completion_date": "2027-06-01", "has_results": false, "last_update_posted_date": "2026-08-11", "last_synced_at": "2026-09-26T11:23:42.738Z", "location_count": 2, "location_summary": "Tucson, Arizona • Cincinnati, Ohio", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Cincinnati", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT04594772" }, { "nct_id": "NCT03714555", "title": "Disulfiram-Copper Gluconate in Met Pancreas Cancer w Rising CA19-9 on Abraxane-Gemzar, FOLFIRINOX or Gemcitabine", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Pancreatic Cancer" ], "interventions": [ { "name": "Safety Laboratories", "type": "DIAGNOSTIC_TEST" }, { "name": "AE Assessment", "type": "OTHER" }, { "name": "Physical Exam", "type": "OTHER" }, { "name": "Concomitant Medication Review", "type": "OTHER" }, { "name": "Tumor Imaging", "type": "DIAGNOSTIC_TEST" }, { "name": "nab-paclitaxel (Abraxane)/gemcitabine (Gemzar) Protocol Plus Disulfiram/Copper Gluconate", "type": "DRUG" }, { "name": "FOLFIRINOX regimen Plus Disulfiram/Copper Gluconate", "type": "DRUG" }, { "name": "Single-agent gemcitabine (Gemzar) regimen Plus Disulfiram/Copper Gluconate", "type": "DRUG" } ], "intervention_types": [ "DIAGNOSTIC_TEST", "OTHER", "DRUG" ], "sponsor": "HonorHealth Research Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "105 Years", "sex": "ALL", "summary": "18 Years to 105 Years" }, "enrollment_count": 1, "start_date": "2019-10-17", "completion_date": "2020-07-29", "has_results": true, "last_update_posted_date": "2023-10-18", "last_synced_at": "2026-09-26T11:23:42.738Z", "location_count": 1, "location_summary": "Scottsdale, Arizona", "locations": [ { "city": "Scottsdale", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT03714555" }, { "nct_id": "NCT02548169", "title": "Dendritic Cell Vaccine and Chemotherapy for Patients With Pancreatic Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Pancreatic Cancer" ], "interventions": [ { "name": "DC Vaccine + Standard of Care Chemotherapy", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Baylor Research Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 7, "start_date": "2015-08", "completion_date": "2017-04-24", "has_results": false, "last_update_posted_date": "2019-01-29", "last_synced_at": "2026-09-26T11:23:42.738Z", "location_count": 1, "location_summary": "Dallas, Texas", "locations": [ { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02548169" } ] }